Skip to main content
. 2020 Jan 15;10:3122. doi: 10.3389/fimmu.2019.03122

Figure 1.

Figure 1

Rb9 peptide inhibits in vivo development of melanoma metastasis in immunocompetent mice. (A) Rb9 intraperitoneal (i.p) administration of 300 μg per animal for 5 alternate days reduce the number of B16F10-Nex2 lung metastatic nodules as compared to vehicle (Veh, PBS); (B) Different doses of i.p. Rb9 administration, 15 days of tumor challenge. *p < 0.05 and ***p < 0.001 calculated using Student's or Welch's t-test, respectively. Vehicle (≥103 counts); (C) Melanotic area on the lung surface, after 15-days tumor cell-challenge. Subcutaneously (s.c.) or intraperitoneally (i.p.) Rb9-treated mice, scrambled peptide (Scr-Rb9). Median, 25 and 75% quartiles, ± max and min values. *p < 0.05 and **p < 0.01. One-Way ANOVA with Bonferroni correction; (D) Representative panel of lungs after i.p. or s.c. Rb9 administration; (E) Immuno-compromised mice (NOD/Scid/IL-2Rγnull) are not capable to arrest melanoma metastasis development after treatment with 300 μg of Rb9.